Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative SOX and Sintilimab in Hepatoid Adenocarcinoma of Stomach
NCT07178340Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Paclitaxel Micelles for Injection, oxaliplatin, tegafur-gimeracil-oteracil and sintilimab in Hepatoid adenocarcinoma of the stomach (HAS), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Pathological Complete Response Rate. Started Sep 2025; status: recruiting.
02
Drugs
Paclitaxel Micelles for Injectionoxaliplatintegafur-gimeracil-oteracilsintilimab
03
Conditions
Hepatoid adenocarcinoma of the stomach (HAS)
Beyond the preview
Go deeper on NCT07178340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07178340.